The productivity gains associated with a junk food tax and their impact on cost-effectiveness.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
04
2019
accepted:
10
07
2019
entrez:
23
7
2019
pubmed:
23
7
2019
medline:
27
2
2020
Statut:
epublish
Résumé
To estimate the productivity impacts of a policy intervention on the prevention of premature mortality due to obesity. A simulation model of the Australian population over the period from 2003 to 2030 was developed to estimate productivity gains associated with premature deaths averted due to an obesity prevention intervention that applied a 10% tax on unhealthy foods. Outcome measures were the total working years gained, and the present value of lifetime income (PVLI) gained. Impacts were modelled over the period from 2003 to 2030. Costs are reported in 2018 Australian dollars and a 3% discount rate was applied to all future benefits. Premature deaths averted due to a junk food tax accounted for over 8,000 additional working years and a $307 million increase in PVLI. Deaths averted in men between the ages of 40 to 59, and deaths averted from ischaemic heart disease, were responsible for the largest gains. The productivity gains associated with a junk food tax are substantial, accounting for almost twice the value of the estimated savings to the health care system. The results we have presented provide evidence that the adoption of a societal perspective, when compared to a health sector perspective, provides a more comprehensive estimate of the cost-effectiveness of a junk food tax.
Identifiants
pubmed: 31329651
doi: 10.1371/journal.pone.0220209
pii: PONE-D-19-09936
pmc: PMC6645543
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220209Déclaration de conflit d'intérêts
Work associated with the productivity modelling was funded in part by a commercial entity, Pfizer Australia. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Obes Rev. 2008 Sep;9(5):489-500
pubmed: 18331420
Health Policy. 2017 Jun;121(6):715-725
pubmed: 28420538
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
PLoS Med. 2017 Feb 14;14(2):e1002232
pubmed: 28196089
PLoS Med. 2017 Apr 18;14(4):e1002283
pubmed: 28419108
Int J Obes Relat Metab Disord. 1995 Nov;19(11):788-92
pubmed: 8589779
PLoS Med. 2017 Jun 27;14(6):e1002326
pubmed: 28654688
Int J Obes (Lond). 2011 Aug;35(8):1071-8
pubmed: 21224825
J Public Health (Oxf). 2011 Dec;33(4):527-35
pubmed: 21562029
Eur J Health Econ. 2011 Aug;12(4):345-52
pubmed: 20401679
Soc Sci Med. 2011 Jan;72(2):185-92
pubmed: 21146909
Health Aff (Millwood). 2017 Mar 1;36(3):564-571
pubmed: 28228484
Obes Rev. 2006 Aug;7(3):271-93
pubmed: 16866975
Public Health Nutr. 2017 Dec;20(18):3219-3224
pubmed: 29160766
BMC Public Health. 2013 Nov 13;13:1072
pubmed: 24225016
PLoS One. 2016 Apr 13;11(4):e0151460
pubmed: 27073855
Am J Clin Nutr. 2009 Jun;89(6):1723-8
pubmed: 19369382
Obes Rev. 2011 Jan;12(1):50-61
pubmed: 20059703
Expert Rev Pharmacoecon Outcomes Res. 2014 Jun;14(3):355-77
pubmed: 24746223
Eur J Clin Nutr. 2016 Jun;70(6):681-6
pubmed: 27071513
Aust N Z J Public Health. 2012 Dec;36(6):550-6
pubmed: 23216496
Eur Heart J. 2006 Jul;27(13):1610-9
pubmed: 16495286
BMC Res Notes. 2014 Apr 16;7:242
pubmed: 24739239
Pharmacoeconomics. 2006;24(9):869-90
pubmed: 16942122
Int J Obes Relat Metab Disord. 1995 Nov;19 Suppl 6:S13-6
pubmed: 8581114
Am J Prev Med. 2015 Jul;49(1):112-23
pubmed: 26094232
Proc Nutr Soc. 2005 Aug;64(3):359-62
pubmed: 16048669
Int J Obes (Lond). 2011 Jul;35(7):1001-9
pubmed: 21079620
Med J Aust. 2010 Mar 1;192(5):260-4
pubmed: 20201759